Lung - NSCLC and Mesothelioma

MULTI-001 Nivolumab v11

MULTI-002 Carboplatin and etoposide v1

MULTI-003 Pembrolizumab v11

MULTI-004 Atezolizumab (SC/IV) v12

MULTI-018 Larotrectinib v2

MULTI-019 Entrectinib v2

MULTI-020 Dabrafenib with Trametinib v3

MULTI-023 Selpercatinib v2

LUN-006 Pemetrexed v8

LUN-024 Carboplatin & Pemetrexed v6

LUN-027 Crizotinib for ALK positive advanced NSCLC v5

LUN-029 Nintendanib (Vargatef) and Docetaxel for NSCLC v3

LUN-031 Osimertinib v4

LUN-034 Alectinib v2

LUN-035 Durvalumab v5

LUN-036 Pembrolizumab, Carboplatin & Pemetrexed followed by Maintenance Pembrolizumab and Pemetrexed v5

LUN-038 Atezolizumab (sc) in combination with bevacizumab, paclitaxel and carboplatin v5

LUN-039 Brigatinib v2

LUN-040 Weekly paclitaxel & carboplatin concurrent with radiotherapy followed by 3 weekly paclitaxel and carboplatin consolidation* (*consolidation phase can be used in the neo-adjuvant setting prior to chemoradiation) v3

LUN-043 Pembrolizumab, carboplatin and paclitaxel v4

LUN-044 Lorlatinib v2

LUN-045 Nivolumab and Ipilimumab for mesothelioma v3

LUN-046 Tepotinib v1

LUN-047 Sotorasib v2

LUN-049 Nivolumab, Carboplatin and Paclitaxel (neo-adjuvant) v2

LUN-050 Nivolumab, Carboplatin & Pemetrexed (neo-adjuvant) v2